Asad Bashey

Summary

Publications

  1. doi request reprint T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation
    Asad Bashey
    Northside Hospital, Atlanta, GA 30342, USA
    J Clin Oncol 31:1310-6. 2013
  2. doi request reprint Comparison of Outcomes of Hematopoietic Cell Transplants from T-Replete Haploidentical Donors Using Post-Transplantation Cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 Allele-Matched Unrelated Donors and HLA-Identical Sibling Donors: A Mul
    Asad Bashey
    Blood and Marrow Transplant Program, Northside Hospital, Atlanta, Georgia Electronic address
    Biol Blood Marrow Transplant 22:125-33. 2016
  3. pmc Reduced-intensity conditioning allogeneic hematopoietic cell transplantation for patients with hematologic malignancies who relapse following autologous transplantation: a multi-institutional prospective study from the Cancer and Leukemia Group B (CALGB t
    Asad Bashey
    University of California at San Diego, San Diego, CA, USA
    Biol Blood Marrow Transplant 17:558-65. 2011
  4. pmc CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation
    Asad Bashey
    Division of Blood and Marrow Transplantation, University of California, San Diego Moores Cancer Center, La Jolla, CA, USA
    Blood 113:1581-8. 2009
  5. ncbi request reprint Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients under
    Asad Bashey
    Division of Blood and Marrow Transplantation, and Biostatistics Core, Rebecca and John Moores UCSD Cancer Center, La Jolla, California, USA
    Transfusion 47:2153-60. 2007
  6. doi request reprint Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival:
    Scott R Solomon
    Blood and Marrow Transplant Program at Northside Hospital, Atlanta, Georgia, USA
    Biol Blood Marrow Transplant 18:1859-66. 2012
  7. ncbi request reprint Non-anthracycline based remission induction therapy for newly diagnosed patients with acute myeloid leukemia aged 60 or older
    Asad Bashey
    Department of Medicine, University of California, San Diego, 9500 Gilman Dr, Mail Code 0960, La Jolla, CA 92093 0960, USA
    Leuk Res 30:503-6. 2006
  8. doi request reprint Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab
    Scott R Solomon
    Blood and Marrow Transplant Program at Northside Hospital, Atlanta, Georgia Electronic address
    Biol Blood Marrow Transplant 21:1576-82. 2015
  9. doi request reprint Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors
    Scott R Solomon
    Blood and Marrow Transplant Program, Northside Hospital, Atlanta, Georgia Electronic address
    Biol Blood Marrow Transplant 21:1299-307. 2015
  10. doi request reprint Autologous hematopoietic stem cell transplantation as an intensive consolidation therapy for adult patients in remission from acute myelogenous leukemia
    Andre S Jung
    Department of Medicine, University of California, San Diego, La Jolla, California 92093 0960, USA
    Biol Blood Marrow Transplant 15:1306-13. 2009

Collaborators

Detail Information

Publications16

  1. doi request reprint T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation
    Asad Bashey
    Northside Hospital, Atlanta, GA 30342, USA
    J Clin Oncol 31:1310-6. 2013
    ..We compared outcomes of alloHCT using haploidentical donors with those of transplantation using conventional HLA-matched sibling donors (MRDs) and HLA-matched unrelated donors (MUDs)...
  2. doi request reprint Comparison of Outcomes of Hematopoietic Cell Transplants from T-Replete Haploidentical Donors Using Post-Transplantation Cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 Allele-Matched Unrelated Donors and HLA-Identical Sibling Donors: A Mul
    Asad Bashey
    Blood and Marrow Transplant Program, Northside Hospital, Atlanta, Georgia Electronic address
    Biol Blood Marrow Transplant 22:125-33. 2016
    ..59; P = .007). HIDT produced similar long-term survival with lower rates of chronic GVHD than optimally matched MUDT. HIDT should be considered a standard of care option for patients lacking a matched sibling donor. ..
  3. pmc Reduced-intensity conditioning allogeneic hematopoietic cell transplantation for patients with hematologic malignancies who relapse following autologous transplantation: a multi-institutional prospective study from the Cancer and Leukemia Group B (CALGB t
    Asad Bashey
    University of California at San Diego, San Diego, CA, USA
    Biol Blood Marrow Transplant 17:558-65. 2011
    ..0395). Allo-HCT using this reduced-intensity conditioning regimen can be performed with low TRM in patients who have received a prior AHCT. Efforts to improve early donor CD3 chimerism may improve event-free survival...
  4. pmc CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation
    Asad Bashey
    Division of Blood and Marrow Transplantation, University of California, San Diego Moores Cancer Center, La Jolla, CA, USA
    Blood 113:1581-8. 2009
    ..This study is registered at (http://clinicaltrials.gov) under NCI protocol ID P6082...
  5. ncbi request reprint Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients under
    Asad Bashey
    Division of Blood and Marrow Transplantation, and Biostatistics Core, Rebecca and John Moores UCSD Cancer Center, La Jolla, California, USA
    Transfusion 47:2153-60. 2007
    ..This necessitates the availability of leukapheresis (LP) facilities 7 days a week...
  6. doi request reprint Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival:
    Scott R Solomon
    Blood and Marrow Transplant Program at Northside Hospital, Atlanta, Georgia, USA
    Biol Blood Marrow Transplant 18:1859-66. 2012
    ..Myeloablative haploidentical HSCT is associated with excellent rates of engraftment, GVHD, NRM, and DFS, and is a valid option in patients with high-risk malignancies who lack timely access to a conventional donor...
  7. ncbi request reprint Non-anthracycline based remission induction therapy for newly diagnosed patients with acute myeloid leukemia aged 60 or older
    Asad Bashey
    Department of Medicine, University of California, San Diego, 9500 Gilman Dr, Mail Code 0960, La Jolla, CA 92093 0960, USA
    Leuk Res 30:503-6. 2006
    ..Primary induction with FLAG in elderly AML patients achieves a high remission rate without prohibitive mucosal or cardiac toxicity and may thus be considered as an alternative to standard anthracycline-based regimens in this setting...
  8. doi request reprint Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab
    Scott R Solomon
    Blood and Marrow Transplant Program at Northside Hospital, Atlanta, Georgia Electronic address
    Biol Blood Marrow Transplant 21:1576-82. 2015
    ....
  9. doi request reprint Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors
    Scott R Solomon
    Blood and Marrow Transplant Program, Northside Hospital, Atlanta, Georgia Electronic address
    Biol Blood Marrow Transplant 21:1299-307. 2015
    ..Outcomes appear at least equivalent to those seen in contemporaneous patients who underwent transplantation from MUD...
  10. doi request reprint Autologous hematopoietic stem cell transplantation as an intensive consolidation therapy for adult patients in remission from acute myelogenous leukemia
    Andre S Jung
    Department of Medicine, University of California, San Diego, La Jolla, California 92093 0960, USA
    Biol Blood Marrow Transplant 15:1306-13. 2009
    ..In addition, there was no treatment-related mortality (TRM). We conclude that APBSCT is a reasonable and safe intensive consolidation for patients with AML who do not have a suitable HLA-matched donor...
  11. pmc CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cells
    Jiehua Zhou
    Moores Cancer Center, University of California San Diego, La Jolla, California, USA
    Biol Blood Marrow Transplant 17:682-92. 2011
    ..Further studies with multiple doses are needed to explore this phenomenon further and to correlate changes in lymphocyte subpopulations with clinical events...
  12. doi request reprint Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation
    Scott R Solomon
    Blood and Marrow Transplant Program, Northside Hospital, Atlanta, Georgia Electronic address
    Biol Blood Marrow Transplant 20:1828-34. 2014
    ..GVHD prophylaxis with PTCy and sirolimus achieves consistent donor engraftment, low rates of chronic GVHD and NRM, and excellent outcomes in recipients of HLA-identical related and unrelated donor allogeneic PBSCT...
  13. ncbi request reprint Immunosuppression with limited toxicity: the characteristics of nucleoside analogs and anti-lymphocyte antibodies used in non-myeloablative hematopoietic cell transplantation
    Asad Bashey
    Blood and Marrow Transplantation Division, University of California San Diego, Department of Medicine, UCSD Cancer Center, La Jolla, CA 92093 0960, USA
    Cancer Treat Res 110:39-49. 2002
    ..Although fludarabine has been the mainstay of nucleoside analog usage for NST, the other nucleoside analogs-cladribine and pentostatin are beginning to be investigated in this context...
  14. pmc Comparison of twin and autologous transplants for multiple myeloma
    Asad Bashey
    BMT Group of Georgia, Atlanta, GA, USA
    Biol Blood Marrow Transplant 14:1118-24. 2008
    ..49, 95% confidence interval [CI] 0.28-0.86, P = .011). Twin transplants have a significantly lower relapse risk than autotransplants in MM, suggesting that graft composition may impact outcomes following high-dose chemotherapy...
  15. pmc Real-life experience of a brief arsenic trioxide-based consolidation chemotherapy in the management of acute promyelocytic leukemia: favorable outcomes with limited anthracycline exposure and shorter consolidation therapy
    Mindy Leech
    Blood and Marrow Transplant Program, Northside Hospital, Atlanta, GA
    Clin Lymphoma Myeloma Leuk 15:292-7. 2015
    ..However, its efficacy against high-risk APL (white blood cell count > 10,000/μL) has not been documented. Also, it requires ≥ 8 months to complete therapy...
  16. pmc Lenalidomide after stem-cell transplantation for multiple myeloma
    Philip L McCarthy
    Blood and Marrow Transplant Program, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    N Engl J Med 366:1770-81. 2012
    ..Data are lacking on whether lenalidomide maintenance therapy prolongs the time to disease progression after autologous hematopoietic stem-cell transplantation in patients with multiple myeloma...